×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RDHL – redhill biopharma ltd. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RDHL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/10
07:16 am
rdhl
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development [Yahoo! Finance]
High
Report
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development [Yahoo! Finance]
12/10
07:00 am
rdhl
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Medium
Report
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
12/2
07:10 am
rdhl
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court [Yahoo! Finance]
High
Report
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court [Yahoo! Finance]
12/2
07:00 am
rdhl
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
Medium
Report
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
10/28
07:00 am
rdhl
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
Low
Report
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
10/22
07:00 am
rdhl
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
Medium
Report
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
10/14
07:00 am
rdhl
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
Medium
Report
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
10/1
07:00 am
rdhl
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Medium
Report
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020
26.1%
4/2 RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca 12.6%
4/13 RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel 10.6%
4/20 Form 6-K RedHill Biopharma Ltd. For: Apr 20 10.5%
7/12 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at WBB Securities from a "buy" rating to a "strong-buy" rating. They now have a $17.00 price target on the stock. 8.2%
3/23 Form 6-K RedHill Biopharma Ltd. For: Mar 23 7.9%
4/6 RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use 7.7%
4/27 Form 6-K RedHill Biopharma Ltd. For: Apr 27 7.5%
3/4 RedHill Biopharma (RDHL) Q4 2019 Earnings Call Transcript [The Motley Fool] 6.3%
12/23 3 Stocks with Growth Prospects in the Triple Digits [Yahoo! Finance News] 4.6%
4/2 RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca 12.6%
4/13 RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel 10.6%
4/20 Form 6-K RedHill Biopharma Ltd. For: Apr 20 10.5%
7/12 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at WBB Securities from a "buy" rating to a "strong-buy" rating. They now have a $17.00 price target on the stock. 8.2%
3/23 Form 6-K RedHill Biopharma Ltd. For: Mar 23 7.9%
4/6 RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use 7.7%
4/27 Form 6-K RedHill Biopharma Ltd. For: Apr 27 7.5%
3/4 RedHill Biopharma (RDHL) Q4 2019 Earnings Call Transcript [The Motley Fool] 6.3%
12/23 3 Stocks with Growth Prospects in the Triple Digits [Yahoo! Finance News] 4.6%
TOP News Decliners
11/4
UPDATE 1-U.S. FDA approves RedHill's bacterial infection treatment [Yahoo! Finance News]
-19.7%
3/11 Form 6-K RedHill Biopharma Ltd. For: Mar 11 -17.7%
2/27 RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020 -13.6%
10/11 RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease -13.5%
4/28 RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary -13.0%
3/9 Form 6-K RedHill Biopharma Ltd. For: Mar 09 -12.6%
7/22 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -12.1%
3/23 RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26 -11.7%
3/17 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -10.5%
2/6 REDHILL BIOPHAR/S (NASDAQ: RDHL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
3/11 Form 6-K RedHill Biopharma Ltd. For: Mar 11 -17.7%
2/27 RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020 -13.6%
10/11 RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease -13.5%
4/28 RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary -13.0%
3/9 Form 6-K RedHill Biopharma Ltd. For: Mar 09 -12.6%
7/22 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -12.1%
3/23 RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26 -11.7%
3/17 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -10.5%
2/6 REDHILL BIOPHAR/S (NASDAQ: RDHL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: